Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681999 | 1.00 | TDP1 (0.39) | TDP1TAS2R14RIPK1BCL2A1ALDH1A1 | |
| SCHEMBL5797871 | 1.00 | TDP1 (0.39) | TDP1TAS2R14RIPK1BCL2A1ALDH1A1 | |
| SCHEMBL6077241 | 0.89 | CA12 (0.42) | TDP1TAS2R14RIPK1BCL2A1ALDH1A1 | |
| SCHEMBL6077249 | 0.89 | CA12 (0.42) | TDP1TAS2R14RIPK1BCL2A1ALDH1A1 | |
| SCHEMBL6879068 | 0.87 | CTBP2 (0.36) | TAS2R14ALDH1A1LMNAMAPTCA12 | |
| SCHEMBL6879062 | 0.87 | CTBP2 (0.36) | TAS2R14ALDH1A1LMNAMAPTCA12 | |
| SCHEMBL6872170 | 0.87 | NPC1 (0.40) | LMNACA12CA9CA1CA2 | |
| SCHEMBL6872168 | 0.87 | NPC1 (0.40) | LMNACA12CA9CA1CA2 | |
| SCHEMBL6871375 | 0.86 | TAAR1 (0.41) | TDP1ALDH1A1CA12CA1CA2 | |
| SCHEMBL6871370 | 0.86 | TAAR1 (0.41) | TDP1ALDH1A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732604-B1 | METHODS OF TREATING HIV INFECTION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | claimed |
| EP-1732604-A2 | METHODS OF TREATING HIV INFECTION | Bristol-Myers Squibb Company (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2006034001-A2 | METHODS OF TREATING HIV INFECTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060058286-A1 | Methods of treating HIV infection | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-16 | — | — | US | claimed |
| WO-2005102391-A1 | COMBINATIONS FOR THE TREATMENT OF AIDS OR HIV INFECTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102392-A2 | COMBINATIONS FOR TREATING HIV INFECTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-03 | — | — | WO | claimed |
| WO-2005102328-A1 | METHODS OF TREATING HIV INFECTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-03 | — | — | WO | claimed |
| US-20050215545-A1 | Methods of treating HIV infection | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2005-09-29 | — | — | US | claimed |
| US-20050215544-A1 | Methods of treating HIV infection | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | claimed |
| US-20050215543-A1 | Methods of treating HIV infection | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-29 | — | — | US | claimed |
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | claimed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | claimed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | claimed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | claimed |
| US-7776863-B2 | Methods of treating HIV infection | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1732604-B1 | METHODS OF TREATING HIV INFECTION | BRISTOL MYERS SQUIBB CO (US) | 2010-07-21 | — | — | EP | disclosed |
| EP-1732604-A2 | METHODS OF TREATING HIV INFECTION | Bristol-Myers Squibb Company (US) | 2006-12-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215544-A1 | Methods of treating HIV infection | CCR5, CD4, CCR1 | TDP1 2644/4885TAS2R14 4812/4885RIPK1 2441/4885 |
| US-20050215545-A1 | Methods of treating HIV infection | CCR5, CD4, CCR1 | TDP1 2644/4885TAS2R14 4812/4885RIPK1 2441/4885 |
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | TDP1 10/4885TAS2R14 4569/4885RIPK1 1438/4885 |
| US-20050215543-A1 | Methods of treating HIV infection | CCR5, CD4, CCR1 | TDP1 3066/4885TAS2R14 4772/4885RIPK1 1891/4885 |
| US-20060058286-A1 | Methods of treating HIV infection | CCR5, CD4, CCL11 | TDP1 3516/4885TAS2R14 4759/4885RIPK1 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.